Do large mergers increase or decrease the productivity of pharmaceutical R&D?

Area of Science:

• Pharmaceutical industry
• Biotechnology
• Drug discovery and development

Background:

• Mergers in the pharmaceutical sector have uncertain effects on research and development (R&D) productivity.
• Prior empirical analyses show mixed findings regarding the impact of mergers on R&D outcomes.
• Potential mechanisms suggest mergers could either positively or negatively influence R&D productivity.

Purpose of the Study:

• To analyze the impact of large pharmaceutical mergers on R&D productivity using novel methods.
• To investigate the relationship between mergers and downstream measures of R&D success.
• To provide a self-controlled analysis accounting for both R&D inputs and outputs.

Main Methods:

• Utilized downstream measures of R&D productivity for a more accurate assessment.
• Incorporated both R&D inputs and outputs into productivity calculations.
• Employed a self-controlled research design to minimize confounding factors.

Main Results:

• Recent large-scale pharmaceutical mergers demonstrated a statistically significant increase in R&D productivity.
• The findings suggest a positive correlation between merger events and enhanced R&D output.
• Productivity gains are linked to increased depth of scientific information and improved decision-making objectivity.

Conclusions:

• Large pharmaceutical mergers are associated with improved R&D productivity.
• Enhanced scientific information and objective decision-making appear to be key drivers of this improvement.
• The study provides evidence supporting the positive impact of mergers on pharmaceutical innovation.